Home Cart 0 Sign in  
X

[ CAS No. 51-36-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 51-36-5
Chemical Structure| 51-36-5
Chemical Structure| 51-36-5
Structure of 51-36-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 51-36-5 ]

Related Doc. of [ 51-36-5 ]

Alternatived Products of [ 51-36-5 ]

Product Details of [ 51-36-5 ]

CAS No. :51-36-5 MDL No. :MFCD00002494
Formula : C7H4Cl2O2 Boiling Point : -
Linear Structure Formula :- InChI Key :CXKCZFDUOYMOOP-UHFFFAOYSA-N
M.W : 191.01 Pubchem ID :5811
Synonyms :

Calculated chemistry of [ 51-36-5 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 43.42
TPSA : 37.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.34 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.61
Log Po/w (XLOGP3) : 3.0
Log Po/w (WLOGP) : 2.69
Log Po/w (MLOGP) : 2.79
Log Po/w (SILICOS-IT) : 2.5
Consensus Log Po/w : 2.52

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -3.25
Solubility : 0.107 mg/ml ; 0.00056 mol/l
Class : Soluble
Log S (Ali) : -3.45
Solubility : 0.0681 mg/ml ; 0.000357 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.01
Solubility : 0.188 mg/ml ; 0.000986 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.2

Safety of [ 51-36-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 51-36-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 51-36-5 ]
  • Downstream synthetic route of [ 51-36-5 ]

[ 51-36-5 ] Synthesis Path-Upstream   1~14

  • 1
  • [ 51-36-5 ]
  • [ 3290-06-0 ]
Reference: [1] Pest Management Science, 2000, vol. 56, # 10, p. 875 - 881
  • 2
  • [ 51-36-5 ]
  • [ 2978-58-7 ]
  • [ 23950-58-5 ]
Reference: [1] Organic Process Research and Development, 1999, vol. 3, # 3, p. 172 - 176
  • 3
  • [ 51-36-5 ]
  • [ 60211-57-6 ]
Reference: [1] Canadian Journal of Chemistry, 1978, vol. 56, p. 1721 - 1723
[2] Synlett, 1997, vol. 1997, # 8, p. 989 - 991
[3] Pest Management Science, 2000, vol. 56, # 10, p. 875 - 881
  • 4
  • [ 463-73-0 ]
  • [ 51-36-5 ]
  • [ 60211-57-6 ]
Reference: [1] Patent: US6255301, 2001, B1,
  • 5
  • [ 10203-08-4 ]
  • [ 60211-57-6 ]
  • [ 51-36-5 ]
Reference: [1] Monatshefte fuer Chemie, 1933, vol. 62, p. 344,347
[2] Monatshefte fuer Chemie, 1933, vol. 62, p. 344,347
  • 6
  • [ 51-36-5 ]
  • [ 10203-08-4 ]
Reference: [1] Journal of the Chemical Society [Section] B: Physical Organic, 1966, p. 1011 - 1015
  • 7
  • [ 51-36-5 ]
  • [ 917-54-4 ]
  • [ 14401-72-0 ]
  • [ 184970-30-7 ]
Reference: [1] Journal of the American Chemical Society, 1983, vol. 105, # 6, p. 1578 - 1584
  • 8
  • [ 51-36-5 ]
  • [ 593-74-8 ]
  • [ 56961-33-2 ]
Reference: [1] Patent: CN105859574, 2016, A, . Location in patent: Paragraph 0007
  • 9
  • [ 51-36-5 ]
  • [ 124-41-4 ]
  • [ 82477-67-6 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 22, p. 6419 - 6423
[2] Medicinal Chemistry Research, 2017, vol. 26, # 9, p. 2161 - 2171
[3] European Journal of Medicinal Chemistry, 2018, vol. 156, p. 230 - 239
[4] Heterocycles, 1985, vol. 23, # 6, p. 1483 - 1491
[5] Patent: WO2007/39736, 2007, A1, . Location in patent: Page/Page column 40
[6] Patent: US2008/293775, 2008, A1, . Location in patent: Page/Page column 23
[7] Chemical Biology and Drug Design, 2013, vol. 82, # 3, p. 336 - 347
  • 10
  • [ 51-36-5 ]
  • [ 82477-67-6 ]
Reference: [1] Patent: US2008/293775, 2008, A1, . Location in patent: Page/Page column 25
  • 11
  • [ 67-56-1 ]
  • [ 51-36-5 ]
  • [ 82477-67-6 ]
Reference: [1] Archiv der Pharmazie, 2011, vol. 344, # 3, p. 197 - 204
  • 12
  • [ 51-36-5 ]
  • [ 20776-67-4 ]
Reference: [1] Patent: CN105859574, 2016, A,
  • 13
  • [ 51-36-5 ]
  • [ 890707-28-5 ]
Reference: [1] Patent: CN105859574, 2016, A,
  • 14
  • [ 51-36-5 ]
  • [ 68-12-2 ]
  • [ 153203-80-6 ]
YieldReaction ConditionsOperation in experiment
82%
Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 2 h;
Stage #2: at 20℃;
The reaction kettle is added compound XVI (190g, 1.0 µM), anhydrous THF (1L) dissolved, cooling to -78 °C, slowly adds by drops positively BuLi (2.5M, 0 . 5L), to maintain the temperature of the reaction 2 hours after DMF slowly adds by drops anhydrously (95g, 1.3 µM), the reaction temperature to room temperature slowly to the disappearance of the raw material, to join the semi-saturated ammonium chloride quenching, ethyl acetate after extracting the concentrated white solid, petroleum ether ethyl acetate system beating shall be required compound XII (179g, 82percent).
80%
Stage #1: With lithium diisopropyl amide In tetrahydrofuran at -78℃; Inert atmosphere
Stage #2: for 2 h;
Take 3,5-dichlorobenzoic acid (191mg, 1mmol) was dissolved in 5mL of anhydrous tetrahydrofuran, and argon protection, followed by cooling to -78 .At this temperature, slowly added dropwise 2N lithium diisopropylamide (LDA) in tetrahydrofuran (0.6 mL, 1.2mmol).Stirring was continued for 0.5 ~ 1h after addition was complete.It was then slowly added dropwise a solution of 0.5mL DMF 2mL of tetrahydrofuran, was added after the reaction was continued for 2h, TLC detection, reaction was almost completed. The residue was quenched with 1N dilute hydrochloric acid and evaporated to dryness. The residue was purified by column chromatography using ethyl acetate and water and the ethyl ester layer to give the title compound 3,5-dichloro-4-formylbenzoic acid (175 mg , 80percent).
Reference: [1] Patent: CN106565625, 2017, A, . Location in patent: Paragraph 0073-0074
[2] Patent: CN104341316, 2017, B, . Location in patent: Paragraph 0379; 0381; 0382
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 51-36-5 ]

Chlorides

Chemical Structure| 56961-33-2

[ 56961-33-2 ]

3-Chloro-5-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 7499-07-2

[ 7499-07-2 ]

4-Chloro-2-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 4506-45-0

[ 4506-45-0 ]

5-Chloro-2-formylbenzoic acid

Similarity: 0.98

Chemical Structure| 535-80-8

[ 535-80-8 ]

3-Chlorobenzoic acid

Similarity: 0.96

Chemical Structure| 74-11-3

[ 74-11-3 ]

4-Chlorobenzoic acid

Similarity: 0.96

Carboxylic Acids

Chemical Structure| 56961-33-2

[ 56961-33-2 ]

3-Chloro-5-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 7499-07-2

[ 7499-07-2 ]

4-Chloro-2-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 4506-45-0

[ 4506-45-0 ]

5-Chloro-2-formylbenzoic acid

Similarity: 0.98

Chemical Structure| 535-80-8

[ 535-80-8 ]

3-Chlorobenzoic acid

Similarity: 0.96

Chemical Structure| 74-11-3

[ 74-11-3 ]

4-Chlorobenzoic acid

Similarity: 0.96